LEADS BIOLABS-B (09887): Trustee purchases 220,700 H shares under the H-share award scheme
LEADS BIOLABS-B (09887) announced that on November 16, 2026, the trustee purchased 220,700 H shares (Share Purchase) on The Stock Exchange of Hong Kong Limited under the H-share award scheme, at a total consideration of HK$7.3726 million.
LEADS BIOLABS-B (09887) announced that on November 16, 2026, the trustee purchased 220,700 H shares on The Stock Exchange of Hong Kong Limited under the H-share award scheme (the share purchase), for a total consideration of HK$7.3726 million.
The Company may continue to instruct the trustee to purchase H shares through open market transactions in accordance with the rules of the H-share award scheme.
The Board believes that the share purchase demonstrates the Company's confidence in its business outlook and prospects, and will bring long-term benefits to the Company and enhance shareholder value. The Board further believes that the Company has sufficient financial resources to implement the share purchase while maintaining a sound financial position.
Related Articles
CARRY WEALTH (00643) clarifies that Hu Dongmei has not become and is not a director of the company.

Deshi Technology (02526) is about to globally debut the upgraded iMedLoop, connecting the "personal + clinical + research" three entry points for the first time.

BOAN BIOTECH (06955): BA1104 (nivolumab) China Phase III clinical trial completed and met primary endpoint
CARRY WEALTH (00643) clarifies that Hu Dongmei has not become and is not a director of the company.
Deshi Technology (02526) is about to globally debut the upgraded iMedLoop, connecting the "personal + clinical + research" three entry points for the first time.

BOAN BIOTECH (06955): BA1104 (nivolumab) China Phase III clinical trial completed and met primary endpoint






